All News
Filter News
Found 96 articles
-
Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.
-
Novartis has abandoned its ex vivo sickle cell disease program developed using Intellia Therapeutics’ CRISPR gene editing platform, Intellia announced Thursday.
-
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
2/22/2023
Graphite Bio, Inc. announced that it has completed a review of its business, including the status of its programs, resources and capabilities.
-
Adaptimmune Announces Changes to Board of Directors
2/16/2023
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced that Kristen M. Hege, M.D. will join its board of directors.
-
Graphite Bio announced it is voluntarily pausing the Phase I/II study of its lead candidate nula-cel in sickle cell disease.
-
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
1/5/2023
Graphite Bio, Inc. announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event is likely related to study treatment.
-
The FDA lifted its partial clinical hold on bluebird's experimental sickle cell disease gene therapy for patients younger than 18.
-
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
12/11/2022
Graphite Bio, Inc. presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel, an investigational gene-edited therapy for sickle cell disease.
-
Editas Medicine released positive proof of concept data Tuesday morning from the first patients dosed with its experimental CRISPR-based gene therapy for sickle cell disease.
-
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
11/21/2022
Graphite Bio, Inc. today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.
-
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
11/9/2022
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and third quarter 2022 financial results.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
-
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
10/11/2022
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention.
-
Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
9/13/2022
Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, has been named to Nature Biotechnology's list of leading spinouts of 2021.
-
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
9/8/2022
Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. will host the 11th Annual Sickle Cell Disease Therapeutics Conference on Wednesday, September 14th.
-
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
-
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
8/11/2022
Graphite Bio, Inc. today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD).
-
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
8/11/2022
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.
-
Women of color continue to be trailblazers in the life science industry, proving that they can be just as, if not more, successful than their peers - even if it isn’t always easy.